Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease

NCT02615002 is registered in ClinicalTrials.gov with Neurim Pharmaceuticals Ltd. as lead sponsor.

NCT NCT02615002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02615002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease
Lead sponsor
Neurim Pharmaceuticals Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
November 19, 2019
Enrollment
371 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease